Discuss the clinical benefit of allogeneic hematopoietic stem cell transplantation (HSCT) in older patients with MDS
Describe the clinical relevance of genomic profiling in MDS
Provide evidence for the utility of genomic information to define eligibility for and the optimal timing of transplantation
Two patients aged 72 and 71 years, referred to as patient A and patient B, respectively, were admitted to our institution in March 2022. Both presented with blood cytopenia and were diagnosed with myelodysplastic syndrome (MDS) with multilineage dysplasia according to World Health Organization 2016 criteria. Bone marrow blasts were less than 5%, and karyotype was normal in both cases. Mutation screening revealed an isolated TP53 gene mutation in patient A and mutations in TET2 and SRSF2 genes in patient B. Accordingly, both patients were classified as intermediate Revised International Prognostic Scoring System (IPSS-R) risk...
